CN112568441A - Composition for enhancing immunity and preparation method thereof - Google Patents
Composition for enhancing immunity and preparation method thereof Download PDFInfo
- Publication number
- CN112568441A CN112568441A CN202011532280.2A CN202011532280A CN112568441A CN 112568441 A CN112568441 A CN 112568441A CN 202011532280 A CN202011532280 A CN 202011532280A CN 112568441 A CN112568441 A CN 112568441A
- Authority
- CN
- China
- Prior art keywords
- weight
- composition
- peptide
- parts
- maltodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 111
- 230000036039 immunity Effects 0.000 title claims abstract description 47
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 89
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 52
- 102000008186 Collagen Human genes 0.000 claims abstract description 38
- 108010035532 Collagen Proteins 0.000 claims abstract description 38
- 229920001436 collagen Polymers 0.000 claims abstract description 38
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 26
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 26
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 26
- 235000020234 walnut Nutrition 0.000 claims abstract description 26
- 229920002774 Maltodextrin Polymers 0.000 claims description 39
- 239000005913 Maltodextrin Substances 0.000 claims description 39
- 229940035034 maltodextrin Drugs 0.000 claims description 39
- 241000758789 Juglans Species 0.000 claims description 25
- 241000251468 Actinopterygii Species 0.000 claims description 20
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 19
- 239000004376 Sucralose Substances 0.000 claims description 19
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 19
- 239000001630 malic acid Substances 0.000 claims description 19
- 235000011090 malic acid Nutrition 0.000 claims description 19
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 19
- 235000019408 sucralose Nutrition 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 13
- 206010013911 Dysgeusia Diseases 0.000 claims description 11
- 210000000988 bone and bone Anatomy 0.000 claims description 8
- 102000009027 Albumins Human genes 0.000 claims description 7
- 108010088751 Albumins Proteins 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 235000019658 bitter taste Nutrition 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 230000000873 masking effect Effects 0.000 claims description 4
- 230000003860 sleep quality Effects 0.000 abstract description 5
- 240000007049 Juglans regia Species 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 22
- 206010061598 Immunodeficiency Diseases 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000000595 bitter masking effect Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 241001264174 Cordyceps militaris Species 0.000 description 3
- 240000008397 Ganoderma lucidum Species 0.000 description 3
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- MSFSPUZXLOGKHJ-PGYHGBPZSA-N 2-amino-3-O-[(R)-1-carboxyethyl]-2-deoxy-D-glucopyranose Chemical compound OC(=O)[C@@H](C)O[C@@H]1[C@@H](N)C(O)O[C@H](CO)[C@H]1O MSFSPUZXLOGKHJ-PGYHGBPZSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
- A23L5/27—Removal of unwanted matter, e.g. deodorisation or detoxification by chemical treatment, by adsorption or by absorption
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides a composition for enhancing immunity, which comprises 1-6 parts by weight of collagen peptide, 1-6 parts by weight of ossein peptide, 0.03-0.25 part by weight of gamma-aminobutyric acid, 0.0005-0.007 part by weight of walnut peptide and 0.0007-0.004 part by weight of spina date seed extract. The composition can improve immunity and sleep quality, is suitable for administration before sleep, and has wide application range.
Description
Technical Field
The invention belongs to the field of health-care food, and particularly relates to a composition for enhancing immunity and a preparation method thereof.
Background
Immunity is the body's own defense mechanism, and is the body's ability to recognize and destroy any foreign body (virus, bacteria, etc.) that invades from the outside, to treat aged, damaged, dead, denatured self cells, and to recognize and treat mutant cells and virus-infected cells in the body. The body with low immunity is easy to be infected, the body is easy to be ill, and the consumption of the body is aggravated due to frequent illness, so the body generally has the manifestations of weak constitution, malnutrition, listlessness, fatigue, weakness, sleep disorder and the like. In addition, the development of the body and intelligence is poor and serious diseases are induced. Therefore, people with low immunity need to enhance the body immunity, and the enhancement of the immunity means that the self immunity is enhanced by a certain means.
There are many methods for enhancing immunity, such as comprehensive balance of proper nutrition, frequent exercise and moderate work, and studies have shown that a human body can produce a sleep factor called muramic acid during sleep to promote leukocytosis, macrophage activation and liver detoxification function enhancement, thereby eliminating invading bacteria and viruses, so there is a statement that "moderate work is a healthy mother". Modern life is fast in pace, and overtime are normal, so that more and more people can enhance the immunity through simple and fast food nourishing modes such as traditional Chinese medicine preparations, health-care medicines and health-care foods.
For example, chinese patent document CN107136509A discloses a functional food beneficial to improving immunity and a preparation method thereof, which comprises 20-60 parts of fish collagen peptide, 0.2-10 parts of cordyceps militaris polypeptide, 5-15 parts of ginseng extract, 5-50 parts of ganoderma lucidum polysaccharide, 10-60 parts of red date powder, 30-80 parts of inulin, 8-20 parts of stachyose, 1.5-25 parts of gamma-aminobutyric acid and 5-30 parts of spina date seed extract. The invention improves the immunity of organisms by enhancing the phagocytic capacity of macrophages, enhancing the activity of NK cells, enhancing the generation quantity of antibodies and the like, improves the sleep quality and improves the gastrointestinal tract function, and comprehensively solves the low immunity and related comprehensive symptoms. In actual product taking, the product for improving the sleep quality is taken before sleep, and the product for improving the gastrointestinal tract function is taken in the daytime. The cordyceps militaris polypeptide and the ganoderma lucidum polysaccharide are contained in the invention, so that the cordyceps militaris polypeptide and the ganoderma lucidum polysaccharide are not suitable for people with fungus allergy.
Disclosure of Invention
The invention aims to provide a composition capable of improving immunity and a preparation method thereof, the composition can improve the immunity of organisms and sleep quality, is suitable for being taken before sleep, and is wide in applicable crowd range.
The technical scheme of the invention is as follows:
a composition for enhancing immunity comprises, by weight, 1-6 parts of collagen peptide, 1-6 parts of ossein peptide, 0.03-0.25 part of gamma-aminobutyric acid, 0.0005-0.007 part of walnut peptide and 0.0007-0.004 part of spina date seed extract.
The collagen peptide is selected from one or more of fish collagen peptide and albumin polypeptide.
The beverage also comprises 2 to 5 portions of maltodextrin, 0.05 to 0.55 portion of malic acid, 0.01 to 0.045 portion of sucralose and 0.015 to 0.51 portion of essence according to the weight portion.
Preferably, the composition for enhancing immunity comprises, by weight, 2.3-5.5 parts of collagen peptide, 2.3-5.5 parts of ossein peptide, 0.08-0.16 part of gamma-aminobutyric acid, 0.0008-0.004 part of walnut peptide, 0.001-0.003 part of spina date seed extract, 2.8-4.2 parts of maltodextrin, 0.1-0.45 part of malic acid, 0.018-0.036 part of sucralose and 0.15-0.35 part of essence.
Preferably, the composition for enhancing immunity comprises, by weight, 2.86 parts of fish collagen peptide, 0.89 part of albumin polypeptide, 2.75 parts of bone collagen peptide, 0.2 part of gamma-aminobutyric acid, 0.001 part of walnut peptide, 0.001 part of spina date seed extract, 2.768 parts of maltodextrin, 0.3 part of malic acid, 0.025 part of sucralose and 0.205 part of essence.
Preferably, the composition for enhancing immunity comprises, by weight, 3.25 parts of fish collagen peptide, 3.25 parts of bone collagen peptide, 0.1 part of gamma-aminobutyric acid, 0.001 part of walnut peptide, 0.001 part of spina date seed extract, 2.868 parts of maltodextrin, 0.3 part of malic acid, 0.025 part of sucralose and 0.205 part of essence.
The essence is red date essence and orange bitter taste masking essence.
A method for preparing the composition for enhancing immunity comprises the step of uniformly mixing the components to obtain the composition.
The mixing method comprises the step of mixing the walnut peptide, the spina date seed extract and the maltodextrin by adopting an equivalent incremental method.
The mixing times in the equivalent incremental method are 2-7 times; the time for each equivalent incremental mixing is 5-10 min.
The technical scheme of the invention has the following advantages:
1. according to the composition for enhancing immunity, the collagen peptide, the bone collagen peptide and the walnut peptide are cooperated to improve the immunity of an organism and enhance the immunity of a human body; the gamma-aminobutyric acid and the spina date seed extract prolong the sleep time and improve the sleep quality; the components are cooperated to achieve the optimal effect of enhancing the immunity by improving the proportion of the collagen peptide, the ossein peptide, the gamma-aminobutyric acid and the spina date seed extract. And the content of gamma-aminobutyric acid and wild jujube seed extract is reduced, so that the composition is suitable for daily administration.
2. The composition for enhancing immunity provided by the invention does not contain fungi, does not have allergen, and is wide in applicable population range.
3. According to the composition for enhancing immunity, the malic acid, the sucralose and the essence are added according to a specific proportion, so that the unique fishy smell of the peptide is covered, the product has good taste and flavor, and the composition is easily accepted by the public.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, embodiments of the present invention will be described in further detail below. All other embodiments, which can be derived by a person skilled in the art from the embodiments disclosed herein without making any creative effort, shall fall within the protection scope of the present disclosure.
The examples do not show the specific experimental steps or conditions, and can be performed according to the conventional procedures or conditions described in the literature in the field. All reagents are not indicated by manufacturers, and are conventional reagent products which can be obtained commercially. The semen Ziziphi Spinosae extract is a commercial product with water extraction ratio of 10: 1.
Example 1
The embodiment provides a composition for enhancing immunity, which comprises 5g of fish collagen peptide, 4.5g of bone collagen peptide, 0.16g of gamma-aminobutyric acid, 0.005g of walnut peptide and 0.001g of spina date seed extract.
The preparation method comprises the following steps: 5g of fish collagen peptide, 4.5g of bone collagen peptide, 0.16g of gamma-aminobutyric acid, 0.005g of walnut peptide and 0.001g of spina date seed extract are uniformly mixed to obtain the composition 1.
The application and dosage are as follows: is taken once a day, 10g each time, with 200-300ml warm water.
Example 2
The embodiment provides a composition for enhancing immunity, which comprises 3.25g of fish collagen peptide, 3.25g of ossein peptide, 0.1g of gamma-aminobutyric acid, 0.001g of walnut peptide, 0.001g of spina date seed extract, 2.868g of maltodextrin, 0.3g of malic acid, 0.025g of sucralose, 0.2g of red date essence and 0.005g of orange taste bitter taste masking essence.
The preparation method comprises the following steps:
(1) weighing 3.25g of fish collagen peptide, 3.25g of bone collagen peptide, 0.1g of gamma-aminobutyric acid, 0.001g of walnut peptide, 0.001g of spina date seed extract, 2.868g of maltodextrin, 0.3g of malic acid, 0.025g of sucralose, 0.2g of red date essence and 0.005g of orange taste bitter-masking essence for later use;
(2) mixing 0.001g of walnut peptide and 0.001g of maltodextrin for 10min to obtain a premix 1, mixing the premix 1 and 0.002g of maltodextrin for 10min to obtain a premix 2, mixing the premix 2 and 0.004g of maltodextrin for 10min to obtain a premix 3, and mixing the premix 3 and 0.008g of maltodextrin for 10min to obtain a mixture A2;
(3) and (2) premixing: mixing 0.001g of spina date seed extract and 0.001g of maltodextrin for 10min to obtain a premix 1, mixing the premix 1 and 0.002g of maltodextrin for 10min to obtain a premix 2, mixing the premix 2 and 0.004g of maltodextrin for 10min to obtain a premix 3, mixing the premix 3 and 0.008g of maltodextrin for 10min to obtain a premix 4, and mixing the premix 4 and 0.016g of maltodextrin for 10min to obtain a mixture B2;
(4) mixing: mix mixture a2 and mixture B2 with the remaining raw materials for 40min to give composition 2.
The application and dosage are as follows: is taken once a day, 10g each time, with 200-300ml warm water.
Example 3
The embodiment provides a composition for enhancing immunity, which comprises 2.86g of fish collagen peptide, 0.89g of albumin peptide, 2.75g of ossein peptide, 0.2g of gamma-aminobutyric acid, 0.001g of walnut peptide, 0.001g of spina date seed extract, 2.868g of maltodextrin, 0.3g of malic acid, 0.025g of sucralose, 0.2g of red date essence and 0.005g of orange taste bitter masking essence.
The preparation method comprises the following steps:
(1) weighing 2.86g of fish collagen peptide, 0.89g of albumin peptide, 2.75g of ossein peptide, 0.2g of gamma-aminobutyric acid, 0.001g of walnut peptide, 0.001g of spina date seed extract, 2.868g of maltodextrin, 0.3g of malic acid, 0.025g of sucralose, 0.2g of red date essence and 0.005g of orange taste bitter masking essence for later use;
(2) mixing 0.001g of walnut peptide and 0.001g of maltodextrin for 10min to obtain a premix 1, mixing the premix 1 and 0.002g of maltodextrin for 6min to obtain a premix 2, mixing the premix 2 and 0.004g of maltodextrin for 6min to obtain a premix 3, mixing the premix 3 and 0.008g of maltodextrin for 6min to obtain a premix 4, and mixing the premix 4 and 0.016g of maltodextrin for 6min to obtain a mixture A3;
(3) and (2) premixing: mixing 0.001g of spina date seed extract and 0.001g of maltodextrin for 10min to obtain a premix 1, mixing the premix 1 and 0.002g of maltodextrin for 6min to obtain a premix 2, mixing the premix 2 and 0.004g of maltodextrin for 6min to obtain a premix 3, mixing the premix 3 and 0.008g of maltodextrin for 6min to obtain a premix 4, and mixing the premix 4 and 0.016g of maltodextrin for 10min to obtain a mixture B3;
(4) mixing: mix mixture a3 and mixture B3 with the remaining raw materials for 40min to give composition 3.
The application and dosage are as follows: is taken once a day, 10g each time, with 200-300ml warm water.
Example 4
The embodiment provides a composition for enhancing immunity, which comprises 6g of fish collagen peptide, 1g of ossein peptide, 0.08g of gamma-aminobutyric acid, 0.004g of walnut peptide, 0.003g of spina date seed extract, 2.631g of maltodextrin, 0.1g of malic acid, 0.03g of sucralose, 0.15g of red date essence and 0.002g of orange taste bitter masking essence. The preparation was carried out in the same manner as in example 2 to obtain composition 4.
The application and dosage are as follows: is taken once a day, 10g each time, with 200-300ml warm water.
Example 5
The embodiment provides a composition for enhancing immunity, which comprises 2.3g of fish collagen peptide, 5.5g of ossein peptide, 0.16g of gamma-aminobutyric acid, 0.002g of walnut peptide, 0.002g of spina date seed extract, 1.486g of maltodextrin, 0.4g of malic acid, 0.04g of sucralose, 0.1g of red date essence and 0.01g of orange taste bitter masking essence. The preparation was carried out in the same manner as in example 2 to obtain composition 5.
The application and dosage are as follows: is taken once a day, 10g each time, with 200-300ml warm water.
Example 6
The embodiment provides a composition for enhancing immunity, which comprises 1.7g of fish collagen peptide, 4.1g of albumin peptide, 1.37g of bone collagen peptide, 0.16g of gamma-aminobutyric acid, 0.0005g of walnut peptide, 0.004g of spina date seed extract, 1.6685g of maltodextrin, 0.55g of malic acid, 0.04g of sucralose, 0.4g of red date essence and 0.007g of orange taste bitter masking essence. The procedure is as in example 3 to give composition 6.
The application and dosage are as follows: is taken once a day, 10g each time, with 200-300ml warm water.
Comparative example 1
The comparative example provides a composition for enhancing immunity, which comprises 3g of fish collagen peptide, 3.25g of ossein peptide, 0.3g of gamma-aminobutyric acid, 0.001g of walnut peptide, 0.001g of spina date seed extract, 2.918g of maltodextrin, 0.3g of malic acid, 0.025g of sucralose, 0.2g of red date essence and 0.005g of orange taste bitter taste masking essence. The preparation method is the same as that of example 2, and composition 7 is obtained.
The application and dosage are as follows: is taken once a day, 10g each time, with 200-300ml warm water.
The comparative example differs from example 2 in the ratio of fish collagen peptide to gamma-aminobutyric acid.
Comparative example 2
The comparative example provides a composition for enhancing immunity, which comprises 3.25g of fish collagen peptide, 0.1g of gamma-aminobutyric acid, 0.001g of walnut peptide, 0.001g of spina date seed extract, 6.118g of maltodextrin, 0.3g of malic acid, 0.025g of sucralose, 0.2g of red date essence and 0.005g of orange taste bitter masking essence. The preparation method is the same as that of example 2, and composition 8 is obtained.
The application and dosage are as follows: is taken once a day, 10g each time, with 200-300ml warm water.
The comparative example differs from example 2 in that no collagen peptide was added.
Comparative example 3
The comparative example provides a composition for enhancing immunity, which comprises 3.25g of fish collagen peptide, 3.25g of ossein peptide, 0.1g of gamma-aminobutyric acid, 0.001g of spina date seed extract, 2.869g of maltodextrin, 0.3g of malic acid, 0.025g of sucralose, 0.2g of red date essence and 0.005g of orange taste bitter masking essence. The preparation method is the same as that of example 2, and composition 9 is obtained.
The application and dosage are as follows: is taken once a day, 10g each time, with 200-300ml warm water.
The comparative example differs from example 2 in that no walnut peptide was added.
Experimental example immunoregulation experiment for immune-suppressed mice
110 clean female BLAC/c mice, 18-22g, were fed on a standard diet for one week prior to the experiment, and the 110 week mice were randomly divided into 11 groups of 10 mice each, one week after the pre-feeding, and the groups were listed in Table 1. The mice of the blank control group were intraperitoneally injected with 0.2mL of physiological saline, and the mice of the other groups were intraperitoneally injected with 0.2mL of cyclophosphamide (80mg/kg), once a day for 3 consecutive days, to prepare a mouse immunosuppressive model.
From day 4, the official test period was entered. The recommended dosage for human body is 10g/70kg body weight per day, calculated as mouse dose, and the dosage of the low, medium and high dose groups of composition 2 and composition 3 is 0.75g/kg, 1.5g/kg and 4.5g/kg body weight respectively, and the administration is performed by gavage 1 time per day for 28 days. The blank control group and the model control group are filled with 0.2mL of sterilized normal saline every time.
TABLE 1
| Serial number | Group of | Laboratory animal | Test article |
| 1 | Blank control group | Normal mice | Physiological saline |
| 2 | Composition 3 Low dose group | Immunocompromised mice | Composition 3 |
| 3 | Composition 3 Medium dose group | Immunocompromised mice | Composition 3 |
| 4 | Composition 3 high dose group | Immunocompromised mice | Composition 3 |
| 5 | Composition 2 | Immunocompromised mice | Composition 2 |
| 6 | Composition 4 | Immunocompromised mice | Composition 4 |
| 7 | Composition 5 | Immunocompromised mice | Composition 5 |
| 8 | Composition 6 | Immunocompromised mice | Composition 6 |
| 9 | Composition 7 | Immunocompromised mice | Composition 7 |
| 10 | Composition 8 | Immunocompromised mice | Composition 8 |
| 11 | Composition 9 | Immunocompromised mice | Composition 9 |
1. Delayed allergic reaction test
On the lower 24 days of administration of the test substance, each mouse was intraperitoneally injected with 0.2mL of 2% (v/v) SRBC, 4 days after immunization, left hind foot plantar thickness A was measured, then 0.2mL of 20% (v/v) SRBC was subcutaneously injected at the measurement site, left and right foot plantar thickness B was measured at 24h after injection, the same site was measured three times, the average value was taken, and the degree of DTH was expressed as the difference (B-A) between the plantar thicknesses before and after challenge, and the experimental results are shown in Table 2
TABLE 2
As can be seen from table 2, the weight difference between compositions 2 and 6 was significantly higher than that of the blank control group and that of compositions 7 to 9, indicating that the test results of compositions 2 and 6 were positive, and the test results of composition 3 were positive in the low dose group, the medium dose group and the high dose group.
ConA-induced splenic lymphocyte transformation experiments in mice
28 days after administration, each group of mice was aseptically splenized to prepare spleen cell suspensions, and the spleen cell concentrations were adjusted to 3X 10 by using RPMI1640 culture medium6The lymphocyte proliferation reaction was carried out according to the MTT method in the program, and the OD value was finally measured at a wavelength of 570mm on a 721 spectrophotometer. The results of the experiment are shown in FIG. 3.
TABLE 3
| Serial number | Group of | OD value | Serial number | Group of | OD value |
| 1 | Blank control group | 0.111 | 8 | Composition 5 | 0.419 |
| 3 | Composition 3 Low dose group | 0.392 | 9 | Composition 6 | 0.424 |
| 4 | Composition 3 Medium dose group | 0.422 | 10 | Composition 7 | 0.234 |
| 5 | Composition 3 high dose group | 0.446 | 11 | Composition 8 | 0.158 |
| 6 | Composition 2 | 0.428 | 12 | Composition 9 | 0.2226 |
| 7 | Composition 4 | 0.416 |
As can be seen from table 3, the OD values of compositions 2 to 6 were significantly higher than those of the blank control group and higher than those of compositions 7 to 9, indicating that the experimental results of compositions 2 to 6 were positive, and the assay results of composition 3 were positive in the low dose group, the medium dose group and the high dose group.
3. Carbon clearance test of mice
On day 28, each group of mice was injected with 0.1mL/10g of India ink (4-fold dilution) into the tail vein sequentially, and 20. mu.L of the ink was collected from the inner border after the injection of the ink for 2 and 10min, and rapidly added to 2mL of 0.1% sodium carbonate solution and shaken, and the absorbance value was measured at 600mmc using 752-C UV-visible spectrophotometer, and the mice livers and spleens were weighed at the same time, and the phagocytosis index (a) was calculated according to the formula, and the experimental results are shown in Table 4
K＝(lgOD1-lgOD2)/t2-t1
Phagocytic index
TABLE 4
| Serial number | Group of | a value | Serial number | Group of | a value |
| 1 | Blank control group | 4.38 | 8 | Composition 5 | 5.47 |
| 3 | Composition 3 Low dose group | 5.15 | 9 | Composition 6 | 5.61 |
| 4 | Composition 3 Medium dose group | 5.68 | 10 | Composition 7 | 4.98 |
| 5 | Composition 3 high dose group | 6.73 | 11 | Composition 8 | 4.41 |
| 6 | Composition 2 | 5.59 | 12 | Composition 9 | 4.86 |
| 7 | Composition 4 | 5.58 |
As can be seen from table 3, the phagocytic indexes of the compositions 2 to 6 were significantly higher than those of the blank control group and higher than those of the compositions 7 to 9, indicating that the experimental results of the compositions 2 to 6 were positive, and the assay results of the low dose group, the medium dose group and the high dose group of the composition 3 were positive.
Judging the immunity enhancing function according to the detection and evaluation technical specification of the health food: the composition has positive results in any two aspects of cellular immune function, humoral immune function, monocyte-macrophage function and NK cell activity, the tested sample can be judged to have the effect of enhancing the immune function, and the experimental results show that the composition has the effect of enhancing the immune function.
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.
Claims (10)
1. The composition for enhancing immunity is characterized by comprising 1-6 parts by weight of collagen peptide, 1-6 parts by weight of ossein peptide, 0.03-0.25 part by weight of gamma-aminobutyric acid, 0.0005-0.007 part by weight of walnut peptide and 0.0007-0.004 part by weight of spina date seed extract.
2. The composition for enhancing immunity according to claim 1, wherein the collagen peptide is selected from one or more of fish collagen peptide and albumin polypeptide.
3. The composition for enhancing immunity according to claim 1 or 2, further comprising 2 to 5 parts by weight of maltodextrin, 0.05 to 0.55 part by weight of malic acid, 0.01 to 0.045 part by weight of sucralose and 0.015 to 0.51 part by weight of essence.
4. The composition for enhancing immunity according to claim 3, which comprises 2.3-5.5 parts by weight of collagen peptide, 2.3-5.5 parts by weight of ossein peptide, 0.08-0.16 part by weight of gamma-aminobutyric acid, 0.0008-0.004 part by weight of walnut peptide, 0.001-0.003 part by weight of spina date seed extract, 2.8-4.2 parts by weight of maltodextrin, 0.1-0.45 part by weight of malic acid, 0.018-0.036 part by weight of sucralose and 0.15-0.35 part by weight of essence.
5. The composition for enhancing immunity according to claim 3, which comprises 2.86 parts of fish collagen peptide, 0.89 part of albumin polypeptide, 2.75 parts of ossein peptide, 0.2 part of gamma-aminobutyric acid, 0.001 part of walnut peptide, 0.001 part of spina date seed extract, 2.768 parts of maltodextrin, 0.3 part of malic acid, 0.025 part of sucralose and 0.205 part of essence by weight.
6. The composition for enhancing immunity according to claim 3, which comprises 3.25 parts by weight of fish collagen peptide, 3.25 parts by weight of bone collagen peptide, 0.1 part by weight of gamma-aminobutyric acid, 0.001 part by weight of walnut peptide, 0.001 part by weight of spina date seed extract, 2.868 parts by weight of maltodextrin, 0.3 part by weight of malic acid, 0.025 part by weight of sucralose and 0.205 part by weight of essence.
7. The composition for enhancing immunity according to claim 1, wherein the flavors are red date flavor and orange taste bitter taste masking flavor.
8. A method of preparing the composition for enhancing immunity according to any one of claims 1 to 7, comprising mixing the components to obtain the composition.
9. The method of claim 8, wherein the mixing step comprises mixing the walnut peptide and the spine date seed extract with maltodextrin using an equal increment method.
10. The method according to claim 9, wherein the number of mixing in the equivalent incremental method is 2 to 7; the time for each equivalent incremental mixing is 5-10 min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011532280.2A CN112568441A (en) | 2020-12-23 | 2020-12-23 | Composition for enhancing immunity and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011532280.2A CN112568441A (en) | 2020-12-23 | 2020-12-23 | Composition for enhancing immunity and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112568441A true CN112568441A (en) | 2021-03-30 |
Family
ID=75138958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011532280.2A Pending CN112568441A (en) | 2020-12-23 | 2020-12-23 | Composition for enhancing immunity and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112568441A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113575825A (en) * | 2021-07-27 | 2021-11-02 | 广东橘香斋大健康产业股份有限公司 | Solid beverage for aiding sleep and beautifying and preparation method thereof |
| CN115251401A (en) * | 2022-06-17 | 2022-11-01 | 兆鑫堂(山东)生物科技有限公司 | Collagen peptide nutritional supplement composition beneficial to immunity improvement and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110077382A1 (en) * | 2008-05-20 | 2011-03-31 | Lili Zhang | Collagen Peptide Having Immune-enhancing Activity from Cyanea Nozakii and Preparation Method and Uses Thereof |
| CN107136509A (en) * | 2017-07-06 | 2017-09-08 | 北京爱博优营养科技有限公司 | It is a kind of to be used to improve functional food of immunity and preparation method thereof |
| CN111557449A (en) * | 2020-05-19 | 2020-08-21 | 北京美信高科科技有限责任公司 | Composition with function of improving immunity and preparation method thereof |
-
2020
- 2020-12-23 CN CN202011532280.2A patent/CN112568441A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110077382A1 (en) * | 2008-05-20 | 2011-03-31 | Lili Zhang | Collagen Peptide Having Immune-enhancing Activity from Cyanea Nozakii and Preparation Method and Uses Thereof |
| CN107136509A (en) * | 2017-07-06 | 2017-09-08 | 北京爱博优营养科技有限公司 | It is a kind of to be used to improve functional food of immunity and preparation method thereof |
| CN111557449A (en) * | 2020-05-19 | 2020-08-21 | 北京美信高科科技有限责任公司 | Composition with function of improving immunity and preparation method thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113575825A (en) * | 2021-07-27 | 2021-11-02 | 广东橘香斋大健康产业股份有限公司 | Solid beverage for aiding sleep and beautifying and preparation method thereof |
| CN115251401A (en) * | 2022-06-17 | 2022-11-01 | 兆鑫堂(山东)生物科技有限公司 | Collagen peptide nutritional supplement composition beneficial to immunity improvement and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107822948B (en) | Composition with after-sun repair, oxidation resistance and whitening effects and preparation method thereof | |
| CN112568441A (en) | Composition for enhancing immunity and preparation method thereof | |
| CN102940086A (en) | Highland barley milk tea and preparation method thereof | |
| CN104323231A (en) | Liver-protecting sobering-up natural composition, liver-protecting sobering-up natural product and preparation method thereof | |
| CN107242422A (en) | It is a kind of to improve immunity of organisms and recover plant molecular peptide solid beverage of physical efficiency and preparation method thereof | |
| CN101637265B (en) | Health food used for improving sleeping | |
| CN109757733A (en) | A kind of oral polypeptide powder and its preparation method and application | |
| CN108813350A (en) | A kind of formula and its preparation process of hypoglycemic, adjuvant treatment diabetes noodles | |
| CN102366099A (en) | Foodstuff suitable for diabetics | |
| CN103750451A (en) | Production method of toadstool healthcare drink | |
| CN106822190B (en) | Composition for enhancing immunity and preparation method thereof | |
| CN101703296B (en) | Pleurotus citrinopileatus drink and preparation method thereof | |
| CN106138101B (en) | A kind of preparation method of chicken embryo placenta extract | |
| CN103108957B (en) | Whole egg protein peptides, preparation method and use thereof | |
| CN112042840A (en) | Preparation method and application of naked oat oligopeptide and beta-glucan compounded blood sugar reducing beverage | |
| CN107998370B (en) | Composition capable of enhancing body motion ability and relieving motion fatigue | |
| CN111616357B (en) | GABA spleen-tonifying and nerve-soothing composition based on homology of medicine and food, preparation and application thereof | |
| CN114794287A (en) | Ginseng and pilose antler coffee and preparation method and application thereof | |
| CN103478843B (en) | A kind of alcohol-decomposing beverage and preparation method thereof | |
| CN103859520B (en) | Contribute to acanthopanax fruit oral liquid and the preparation method of improving water flood function | |
| CN107494863B (en) | Preparation method and application of multifunctional solid beverage | |
| CN112690449A (en) | Cereal conditioning porridge for middle-aged and old people | |
| CN114376212A (en) | Health-care granules with effects of maintaining beauty and keeping young and resisting aging and preparation method thereof | |
| CN106472934B (en) | Mushroom concentrated beverage for improving immunity and preparation method thereof | |
| CN106235313A (en) | A kind of health-care food composition of auxiliary hyperglycemic containing Armeniaca mume Sieb. and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210330 |